571 related articles for article (PubMed ID: 24382738)
21. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Pieri L; Rotunno G; Gisslinger H; Gisslinger B; Müllauer L; Finazzi G; Carobbio A; Gianatti A; Ruggeri M; Nichele I; D'Amore E; Rambaldi A; Tefferi A
Blood; 2012 Mar; 119(10):2239-41. PubMed ID: 22246040
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
Barraco D; Cerquozzi S; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e538. PubMed ID: 28282034
[TBL] [Abstract][Full Text] [Related]
25. A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera.
Jeong JH; Ahn JY; Park PW; Seo YH; Seo JY; Lee JH; Kim KH
Cancer Genet; 2016 Mar; 209(3):112-6. PubMed ID: 26826764
[TBL] [Abstract][Full Text] [Related]
26. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
28. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
29. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
30. Chronic myelomonocytic leukemia transformation in polycythemia vera.
Holcombe RF; Treseler PA; Rosenthal DS
Leukemia; 1991 Jul; 5(7):606-10. PubMed ID: 2072746
[TBL] [Abstract][Full Text] [Related]
31. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
34. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
35. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
37. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
39. [Clinical analysis of 185 patients with polycythemia vera].
Bai J; Shao Z; Jing L; Liu H; Shi J; Zhao M; Fu R; He G; Sun J; Jia H; Qian L; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2002 Nov; 23(11):578-80. PubMed ID: 12482341
[TBL] [Abstract][Full Text] [Related]
40. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]